T1	Participants 76 123	hildren and adolescents with autistic disorder.
T2	Participants 276 325	children and adolescents with autistic disorders.
T3	Participants 394 494	patients (5-17 years of age, who completed the previous fixed-dose, 6 week, double-blind [DB] phase)
